Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 276

Sort by

Sort Order Select

Journal Articles

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Blood (2020) 135 (22): 1929–1945.

https://doi.org/10.1182/blood.2019003507

Published: 2020

Journal Articles

Erdheim-Chester disease

Julien Haroche, Fleur Cohen-Aubart, Zahir Amoura

Blood (2020) 135 (16): 1311–1318.

https://doi.org/10.1182/blood.2019002766

Published: 2020

Journal Articles

Langerhans cell histiocytosis

Carlos Rodriguez-Galindo, Carl E. Allen

Blood (2020) 135 (16): 1319–1331.

https://doi.org/10.1182/blood.2019000934

Published: 2020

Includes: Supplemental data

Journal Articles

A Comprehensive Analysis of Single-Cell Chromatin Accessibility and Gene Expression Identifies Intra-Tumor Heterogeneity and Molecular Treatment Responses in Relapsed/Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 575.

https://doi.org/10.1182/blood-2019-130051

Published: 2019

Journal Articles

Classification and Prognosis of Central Nervous System Involvement in Erdheim-Chester Disease

Fleur Cohen-Aubart, MD PhD, Ahmed Idbaih, MD PhD, Damien Galanaud, MD PhD, Bruno Law-Ye, MD, Jean-François Emile, MD PhD, Frédéric Charlotte, MD, Jean Donadieu, MD PhD, Zahir Amoura, MD MSc, Julien Haroche

Blood (2019) 134 (Supplement_1): 4272.

https://doi.org/10.1182/blood-2019-130606

Published: 2019

Journal Articles

MAPK-ERK Pathway Activation: The Achilles' Heel of IL-7R‒Induced Steroid Resistance

Jordy C.G. Van Der Zwet, MD, Jessica G.C.A.M. Buijs-Gladdines, Willem K. Smits, Zhongli Chen, MSc, Jules P.P. Meijerink, PhD

Blood (2019) 134 (Supplement_1): 1292.

https://doi.org/10.1182/blood-2019-124721

Published: 2019

Journal Articles

Molecular Alterations in Adult Histiocytic Neoplasms

Gaurav Goyal, MBBS, Jithma P. Abeykoon, MD, Nora N Bennani, MD, Minetta C Liu, MD, Mithun Vinod Shah, MD PhD, Ronald S. Go, MD

Blood (2019) 134 (Supplement_1): 2975.

https://doi.org/10.1182/blood-2019-122286

Published: 2019

Journal Articles

Loss of Asxl1 Cooperates with Oncogenic Nras to Drive CMML Progression

Xiaona You, PhD, Zhi Wen, PhD, Guangyao Kong, Adhithi Rajagopalan, BS, Erik A. Ranheim, MD PhD, Yun Zhou, MS, Mrinal M Patnaik, MDMBBS, Jing Zhang, PhD

Blood (2019) 134 (Supplement_1): 3790.

https://doi.org/10.1182/blood-2019-131347

Published: 2019

Journal Articles

Inhibition of BMP-Smad Pathway Reduces Leukemic Stemness in Pediatric AML

Xin Long, PhD, Chris Man, PhD, Padmini Narayanan, PhD, Elizabeth Seashore, MD, Michele Redell, MD PhD

Blood (2019) 134 (Supplement_1): 3731.

https://doi.org/10.1182/blood-2019-129074

Published: 2019

Journal Articles

Therapeutic Stratification of PTEN-MYC Axis Appears to be Promising for Molecular Targeted Therapies in Refractory and Relapsed T-Cell Acute Lymphoblastic Leukemia

Heinz Ahlert, MSc, BSc, Sanil Bhatia, PhD, Marc Remke, MD, Melf Sönnichsen, M.Sc., Niklas Dienstbier, M.Sc., Ute Fischer, PhD, Julia Hauer, MD, Arndt Borkhardt, MD

Blood (2019) 134 (Supplement_1): 3883.

https://doi.org/10.1182/blood-2019-128136

Published: 2019

Journal Articles

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

Filip Janku, MD PhD, Harsh Patel, BS, Vaijayanthi Kandadai Raghavan, Aaron Goodman, Tamara G. Barnes, Razelle Kurzrock, MD

Blood (2019) 134 (Supplement_1): 2319.

https://doi.org/10.1182/blood-2019-126342

Published: 2019

Journal Articles

Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models

Blood (2019) 134 (Supplement_1): 2671.

https://doi.org/10.1182/blood-2019-123418

Published: 2019

Journal Articles

Genome-Wide CRISPR Screening Identifies MAPK and Mtorc Pathways As Regulators of Sorafenib Resistance in Acute Myeloid Leukemia

Alisa Damnernsawad, PhD, Tamilla Nechiporuk, PhD, Daniel Bottomly, MS, Stephen E Kurtz, PhD, Christopher A. Eide, Shannon K. McWeeney, PhD, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 2557.

https://doi.org/10.1182/blood-2019-128877

Published: 2019

Journal Articles

Inhibition of Heme Oxygenase-1 Attenuates Bortezomib Resistance in Multiple Myeloma Via Down-Regulating Gas6 Production

Zhaoyuan Zhang, Weili Wang, MD, Jie Xiong, PhD, Xingyi Kuang, PhD, Dan Ma, MD, Jishi Wang, PhD

Blood (2019) 134 (Supplement_1): 1781.

https://doi.org/10.1182/blood-2019-130474

Published: 2019

Journal Articles

Somatic Mutations Potentiating RAS-MAPK Signaling Confer Resistant Potential Against FLT3-Inhibitors to Acute Myelogenous Leukemia

Masayasu Hayashi, MD PhD, Yoshikane Kikushige, MD PhD, Takuya Harada, MD, Toshihiro Miyamoto, MD PhD, Takahiro Maeda, MD PhD, Koichi Akashi, MD PhD

Blood (2019) 134 (Supplement_1): 910.

https://doi.org/10.1182/blood-2019-130694

Published: 2019

Journal Articles

The MEK Inhibitor Trametinib Enhances Diverse T Cell Reconstitution with Suppressing Xenogeneic Graft-Versus-Host-Disease

Hidekazu Itamura, MD PhD, Hiroyuki Muranushi, MD, Takero Shindo, MD PhD, Kazutaka Kitaura, DVM, PhD, Seiji Okada, MD PhD, Tadasu Shin-I, PhD, Ryuji Suzuki, DVM, PhD, Akifumi Takaori-Kondo, MD PhD, Shinya Kimura, MD PhD

Blood (2019) 134 (Supplement_1): 1929.

https://doi.org/10.1182/blood-2019-128913

Published: 2019

Journal Articles

Investigation of New Therapeutic Compounds for Juvenile Myelomonocytic Leukemia Using Induced Pluripotent Stem Cells with Stably Activated Ras Pathway

Lisa Maria Kuhn, Cyrill Schipp, PhD, Daniel Hein, PhD, Bianca Killing, Nan Qin, PhD, Vera H Jepsen, M.Sc., Heinz Ahlert, MSc, BSc, Jasmin Bartl, PhD, Viktoria Marquardt, M.Sc., David Pauck, Kai Völtzke, M.Sc., Jonathan Lim, PhD, Gabriel Leprivier, PhD, Marc Remke, MD, Sanil Bhatia, PhD, Thorsten Rosenbaum, MD, Arndt Borkhardt, MD, Ute Fischer, PhD

Blood (2019) 134 (Supplement_1): 4651.

https://doi.org/10.1182/blood-2019-131406

Published: 2019

Journal Articles

Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging

Anna Reister Schultz, BS, Thomas Jacob, Christopher A. Eide, Samantha L Savage, Motomi Mori, PhD, Jeffrey W. Tyner, PhD, Cristina E. Tognon, PhD, Tania Q. Vu, Brian J. Druker, MD

Blood (2018) 132 (Supplement 1): 4248.

https://doi.org/10.1182/blood-2018-99-115387

Published: 2018

Journal Articles

RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities

Shady Awad, MD, Matti Kankainen, PhD, Olli Dufva, Caroline A Heckman, PhD, Kimmo Porkka, MD PhD, Satu Mustjoki, MD PhD

Blood (2018) 132 (Supplement 1): 4257.

https://doi.org/10.1182/blood-2018-99-111602

Published: 2018

Journal Articles

Activating KRAS , NRAS , and BRAF Mutants Enhance Proteasome Capacity and Reduce Endoplasmic Reticulum Stress in Multiple Myeloma, Thereby Promoting Plasma Cell Survival and Proteasome Inhibitor Resistance

Fazal Shirazi, PhD, Richard J. Jones, PhD, Isere Kuiatse, PhD, Zuzana Berkova, PhD, Hua Wang, PhD, Hans C. Lee, MD, Samuel Hong, PhD, Ram Kumar Singh, PhD, Lawrence Robert Dick, PhD, Nibedita Chattopadhyay, PhD, Robert Z. Orlowski, MD PhD

Blood (2018) 132 (Supplement 1): 406.

https://doi.org/10.1182/blood-2018-99-117577

Published: 2018

NARROW

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Erdheim-Chester disease

Langerhans cell histiocytosis

A Comprehensive Analysis of Single-Cell Chromatin Accessibility and Gene Expression Identifies Intra-Tumor Heterogeneity and Molecular Treatment Responses in Relapsed/Refractory Multiple Myeloma

Classification and Prognosis of Central Nervous System Involvement in Erdheim-Chester Disease

MAPK-ERK Pathway Activation: The Achilles' Heel of IL-7R‒Induced Steroid Resistance

Molecular Alterations in Adult Histiocytic Neoplasms

Loss of Asxl1 Cooperates with Oncogenic Nras to Drive CMML Progression

Inhibition of BMP-Smad Pathway Reduces Leukemic Stemness in Pediatric AML

Therapeutic Stratification of PTEN-MYC Axis Appears to be Promising for Molecular Targeted Therapies in Refractory and Relapsed T-Cell Acute Lymphoblastic Leukemia

MEK Inhibition with Trametinib in Patients with Non-Langerhans Cell Histiocytosis

Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models

Genome-Wide CRISPR Screening Identifies MAPK and Mtorc Pathways As Regulators of Sorafenib Resistance in Acute Myeloid Leukemia

Inhibition of Heme Oxygenase-1 Attenuates Bortezomib Resistance in Multiple Myeloma Via Down-Regulating Gas6 Production

Somatic Mutations Potentiating RAS-MAPK Signaling Confer Resistant Potential Against FLT3-Inhibitors to Acute Myelogenous Leukemia

The MEK Inhibitor Trametinib Enhances Diverse T Cell Reconstitution with Suppressing Xenogeneic Graft-Versus-Host-Disease

Investigation of New Therapeutic Compounds for Juvenile Myelomonocytic Leukemia Using Induced Pluripotent Stem Cells with Stably Activated Ras Pathway

Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors Using Quantitative Single Cell Phospho-Imaging

RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities

Activating KRAS , NRAS , and BRAF Mutants Enhance Proteasome Capacity and Reduce Endoplasmic Reticulum Stress in Multiple Myeloma, Thereby Promoting Plasma Cell Survival and Proteasome Inhibitor Resistance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only